Arbutus Biopharma (Arbutus Biopharma) Float Percentage Of Total Shares Outstanding : 78.72% (As of May. 23, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arbutus Biopharma's float shares is 148.56 Mil. Arbutus Biopharma's total shares outstanding is 188.72 Mil. Arbutus Biopharma's float percentage of total shares outstanding is 78.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arbutus Biopharma's Insider Ownership is 3.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arbutus Biopharma's Institutional Ownership is 17.95%.

Arbutus Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Arbutus Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	148.56	/	188.72
	=	78.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma (Arbutus Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Executives

Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio	officer: Chief Development Officer	C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8